<!doctype html><html><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no"><title>AGIHouse</title><link rel="stylesheet" href="index.fbe877bc.css"><link rel="stylesheet" href="index.4c335926.css"><link rel="stylesheet" href="index.fd9291ee.css"><link rel="stylesheet" href="index.40b189f7.css"></head><body> <div class="reveal"> <div class="slides"> <div class="footer"> <p class="footer-img pull-left"> Future House </p> <p class="footer-text pull-right"> <span class="footer-link"> <a href="http://futurehouse.org"> http://futurehouse.org</a> </span>|&nbsp;&nbsp; <span class="attn">@andrewwhite01 </span> </p> </div> <section hide-footer class="center" data-background="cloud.png"> <h3> Language is the future of science</h3> <br> <p> Andrew White <br> <small> Future House <br> University of Rochester </small> </p> <p> <small> AGI House SF <br>November, 2023</small> </p> </section> <section data-background-iframe="https://dmol.pub"> </section> <section> <section class="center"> <p>The state of deep learning on molecules</p> </section> <section data-auto-animate class="center" data-background-color="#FFF"> <p data-id="gnn-p">Graph Neural Network</p> <img src="gcn.400b4083.gif"> <p class="small">Graph convolutional neural network example.</p> <div class="footnotes"> White, AD <i> Deep Learning for Molecules & Materials</i> <strong> 2021</strong> </div> </section> </section> <section> <section data-background="#f5f4e9" hide-footer> <img src="synthesis%20schematic.f720fd97.jpeg" class="r-stretch"> </section> <section data-background="#FFF" hide-footer> <p>IUPAC Name to LogS </p> <p class="small"> "The solubility of 1-bromopropane is -1.73 logS"</p> <img src="parities-sol.9d580305.png"> <div class="footnotes"> <p>Caldas M. <i>et al</i> <strong>2023</strong>arXiv:2304.05341 </p> </div> </section> <section data-background="#FFF" hide-footer> <h2>Catalysis</h2> <p class="tiny"> To synthesize Mn-Na2WO4/BN , BN (1.0 g) was impregnated with 4.5 mL of an aqueous solution consiting of Mn ( 0.37 mol) , Na ( 0.37 mol) , W ( 0.185 mol) , at 50 ºC for 6 h. Once activated the reaction is ran at 900 ºC. The total flow rate was 10 mL/min (Ar: 1.5 mL/min, CH4: 5.7 mL/min, O2: 2.8 mL/min), leading to a contact time of 0.75 s. </p> <img src="c2-regression.25198eed.png" class="r-stretch"> </section> </section> <section class="center"> <p>Natural language can be the representation for ML</p> <p class="fragment red">Can it be the output?</p> </section> <section> <section data-background="#FFF" hide-footer> <h2>Natural language explanation</h2>  <div class="row"> <div class="column-3"> <img src="sim_map.a3a79a2a.png"> </div> <div class="column-7"> <img src="sol-ex.b0aced04.png"> </div> </div> <p class="footnotes">A Perspective on Explanations of Molecular Prediction Models. JCTC 2023</p> </section> </section> <section> <section class="center" data-background="#f5f4e9"> The biggest untapped source of data is language. <br> Can we use it directly? </section> <section class="center"> <h2>GPT-4</h2> <p class="small">Which three residues with evolutionary divergence in the G domains of RAS isoforms also impose selectivity constraints of pan-KRAS non-covalent inhibition? </p> <p class="fragment tiny"> The three residues with evolutionary divergence in the G domains of KRAS, HRAS, and NRAS isoforms that impose selectivity constraints for pan-KRAS non-covalent inhibition are Thr35, Asp38, and Glu37. It has been observed that these three amino acids significantly influence the binding affinity and selectivity of potential non-covalent inhibitors, thereby determining the efficacy of different therapeutic strategies targeting the RAS isoforms (Hunter et al., 2015). The understanding of these residues' evolutionary conservation and differences across isoforms can aid the development of more effective pan-RAS inhibitors (Lu et al., 2016). </p> <p class="fragment red"> Wrong, hallucinated reference </p> </section> <section class="center"> <h2>Hallucination Rates</h2> <table class="footnotes"> <tr> <th>LLM</th> <th>Valid(%)</th> <th colspan="3">Hallucinated (%)</th>  <th>N</th> </tr> <tr> <td></td>  <td></td>  <td>Full Hallucination</td> <td>Citation Inaccuracy</td> <td>Context Irrelevance</td> <td></td>  </tr> <tr> <td>GPT-3.5</td> <td>52.50%</td> <td>33.75%</td> <td>12.50%</td> <td>1.25%</td> <td>80</td> </tr> <tr> <td>GPT-4</td> <td>60.78%</td> <td>29.41%</td> <td>3.92%</td> <td>5.88%</td> <td>51</td> </tr> <tr> <td>Claude-2</td> <td>39.71%</td> <td>42.65%</td> <td>4.41%</td> <td>13.24%</td> <td>68</td> </tr> </table> </section> <section class="center"> <p>It takes longer to verify the answer than to do the research</p> </section> <section data-background="#fff" hide-footer> <p>Grounding in context</p> <img src="paperqa.651812eb.png" class="r-stretch"> </section> <section class="center" hide-footer> <h3>Grounded GPT-4</h3> <p class="small">Which three residues with evolutionary divergence in the G domains of RAS isoforms also impose selectivity constraints of pan-KRAS non-covalent inhibition? </p> <p class="fragment tiny"> The three residues with evolutionary divergence in the G domains of RAS isoforms that impose selectivity constraints of pan-KRAS non-covalent inhibition are H95 in the α3 helix of KRAS, and residues 121 and 122 (A121 and A122) in HRAS. The substitution of H95 with L and Q in NRAS and HRAS, respectively, is a notable difference between the isoforms. The residues 121 and 122 distinguish HRAS from NRAS and KRAS and are implicated in allosterically regulating selectivity (Kim2023PanKRASID pages 3-3). </p> <div class="fragment"> <img src="ras-ref.a3249409.png" width="350px"> </div> </section> </section> <section class="center"> <ul> <li>Natural language can be the representation for ML</li> <li>Natural language can be the output for ML</li> <li class="fragment red">What else do we need?</li> </ul> </section> <section data-background="#363636" hide-footer="yes"> <p>GPT-4, how many alcohols are in OCCC(O)c1ccc(O)cc1?</p> <img class="r-stretch" src="gpt-trick.6f025d47.png"> <p class="fragment"> There are two alcohols in the given structure. They are represented by the two -OH groups. </p> </section> <section> <section hide-footer data-background="#FFF"> <h3>neuro-symbolic computing (Agents)</h3> <img src="MRKL.ded7394b.png" class="r-stretch"> <div class="footnotes"> MRKL Systems: A modular, neuro-symbolic architecture that combines large language models, external knowledge sources and discrete reasoning. arXiv:2205.00445 (2022) </div> </section> <section> <p>Do LLMs know tools in chemistry?</p> <table class="tiny"> <thead> <tr> <th>Topic</th> <th>N</th> <th>expert</th> <th>incoder</th> <th>codegen</th> <th>davinci</th> <th>davinci3</th> </tr> </thead> <tbody> <tr> <td>bio</td> <td>13</td> <td>2</td> <td>0%</td> <td>29%</td> <td>43% (0%)<sup>1</sup></td> <td>86%</td> </tr> <tr> <td>cheminf</td> <td>10</td> <td>0</td> <td>20%</td> <td>20%</td> <td>50%</td> <td>50%</td> </tr> <tr> <td>genchem</td> <td>11</td> <td>0</td> <td>29%</td> <td>86%</td> <td>86%</td> <td>86%</td> </tr> <tr> <td>md</td> <td>11</td> <td>3</td> <td>0%</td> <td>13%</td> <td>63% (81%)</td> <td>88%</td> </tr> <tr> <td>plot</td> <td>10</td> <td>10</td> <td>--</td> <td>--</td> <td>-- (57%)</td> <td>--</td> </tr> <tr> <td>qm</td> <td>8</td> <td>3</td> <td>20%</td> <td>60%</td> <td>100% (59%)</td> <td>100%</td> </tr> <tr> <td>sim</td> <td>8</td> <td>5</td> <td>0%</td> <td>0%</td> <td>100% (64%)</td> <td>100%</td> </tr> <tr> <td>spect</td> <td>11</td> <td>1</td> <td>30%</td> <td>20%</td> <td>50% (12%)</td> <td>40%</td> </tr> <tr> <td>stats</td> <td>11</td> <td>1</td> <td>40%</td> <td>80%</td> <td>70% (88%)</td> <td>60%</td> </tr> <tr> <td>thermo</td> <td>10</td> <td>0</td> <td>10%</td> <td>10%</td> <td>80%</td> <td>70%</td> </tr> <tr> <td>total</td> <td>84</td> <td>23</td> <td>17%</td> <td>35%</td> <td>72% (57%)</td> <td>75%</td> </tr> </tbody> </table> <div class="footnotes"> AD White, et al. Digital Discovery, 2023 </div> </section> <section class="center" hide-footer> <h2>Chemistry with Agents</h2> <p>Available tools: web search, pubchem search, LLM code model, calculator, python, synthesis planner, paper-qa </p> <p class="attn fragment"> Question: Design a compound with same mechanism as Dasatinib and purchase it </p> </section> <section hide-footer="yes"> <pre class="tiny">

Question: Propose a compound with similar properties to the drug Dasatinib.
Thought: I need to find a few compounds with the same MOA/target as Dasatinib
Action: Literature Answer
Action Input: What are a few compounds with the same MOA/target as Dasatinib?
Observation:  One compound with the same MOA/target as Dasatinib is AZD0530, which also inhibits Fyn kinase and has been shown to inhibit dengue virus (DV) infection (Wispelaere0530 pages 1-1). Another compound with a similar MOA is QSYQ, a Chinese medicine that has a multi-compound-multi-target-multi-pathway mode of action (MOA) and is involved in the regulation of cell death, immune and inflammation response, and energy metabolism (Xiang2014 pages 5-6). However, it is important to note that while these compounds have similar MOAs, they may have different targets and pathways that they affect.
Thought: I need to modify one of these compounds to make a novel compound
</pre> <pre class="fragment tiny">
Thought: I need to get the SMILES string of one of these compounds
Action: Molecule search
Action Input: imatinib
Observation: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Thought: I need to modify this compound to make a novel compound
Action: Modify compound
Action Input: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Observation: Cc1ccc(NC(=O)c2ccc(CN3CCNCC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
</pre> <pre class="fragment tiny">
Action: Literature Answer
hought: I need to check if this compound is novel
Action: Patent Search
Action Input: Cc1ccc(NC(=O)c2ccc(CN3CCNCC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Observation: Novel
Thought: I need to purchase this compound
Action: Purchase
Action Input: Cc1ccc(NC(=O)c2ccc(CN3CCNCC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Observation: Purchased from ZINC
</pre> </section> <section class="center"> <p class="small"> I now know the final answer Final Answer: The compound Cc1ccc(NC(=O)c2ccc(CN3CCNCC3)cc2)cc1Nc1nccc(-c2cccnc2)n1 is a novel compound with similar properties to Dasatinib and has been purchased from ZINC. </p> </section> <section data-background="#FFF" hide-footer> <h2>ChemCrow</h2> <img src="chempilot_toolset.f568a165.png" class="r-stretch"> <p> ChemCrow Paper: arxiv:2304.05376 <br> Similar agents paper: arXiv:2304.05332 </p> </section> <section data-background="#FFF" hide-footer> <img src="modify_and_synth.2b6b11b8.png" class="r-stretch"> </section> <section data-background="#FFF" hide-footer> <img src="human_AI_interaction.fdb5fc7c.png" class="r-stretch"> </section> <section data-background-iframe="https://future-house.github.io/teaser-website/" hide-footer class="center"> <div class="text-background-dark"> <h2 class="text-dark">Future House</h2> <p class="text-dark">Automating science to accelerate biology</p> </div> </section> <section hide-footer class="center" data-background="#f5f4e9"> <h1>questions</h1> <div class="fill-200"></div> <div class="footnotes"> <p>acknowledgements: </p> nsf che #1764415, nsf cbet #1751471, nsf iis #2029095, nsf dmr #2103553, nih #R35GM137966 </div> </section> </section></div> </div> <script type="module" src="index.ae1b996f.js"></script><script src="index.c53ac727.js" nomodule defer></script> </body></html>